Loading
Require that approved cancer drugs come with a standard set of data (blood levels, drug interactions, toxicity profile) so anyone can design a safe combination trial without asking the company.
Combination trial designers need pharmacokinetic profiles, metabolic pathways, QT effects, myelosuppression kinetics and immunogenicity data that sit in confidential regulatory dossiers. A standardised, machine-readable 'combination-readiness' annex published at approval would let academics and other companies design combination studies and predict overlapping toxicity without bilateral negotiation.
Shares A standard cross-company combination agreement that takes weeks, not years, to sign, Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Secrecy and intellectual property block collaboration, Too many combinations to test.
Shares DrugBank & ChEMBL, FDA Oncology Approvals (OCE) & Novel Drug Approvals.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares DrugBank & ChEMBL, Secrecy and intellectual property block collaboration.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.